PHARMA & DRUGS
(for more information, click title to open PDF file)
A-59 Novel Biomarkers and Agents to Screen Molecular-Targeted Therapeutics for Peritoneal Metastasis from Gastric Cancer
NU Researchers identified Synaptotagmin VIII (SYT8) as a candidate biomarker specific to peritoneal metastasis.
A-60 Novel Biomarkers and Agents to Screen Molecular-Targeted Therapeutics for Hepatic Metastasis from Gastric Cancer
Nagoya University researchers conducted transcriptome analysis using a next-generation sequencing platform and identified major facilitator superfamily domain containing 4 (MFSD4) as a candidate biomarker for hepatic metastasis of GC.
Although it is known that ADAM family proteases cause the severe bleeding from haemorrhagic snake venom, the detailed mechanism of the haemorrhage is unclear. Researchers at Nagoya University have found that the target of ADAM proteases is a Wnt/β-catenin signal receptor, LRP5/6 which controls cell differentiation and proliferation.
The research team at Nagoya University has improved the large-scale T cell culture method and achieved the highest introduction efficiency in a non-viral system; over 50%, by mixing and co-culturing Genetically-modified T Cells with activated T Cells that were separately prepared.
To improve the effect of TCR-T without modifying TCR affinity, researchers at Nagoya University have developed two artificial T cell activating adapter molecules (ATAMs), CD3ζ/CD28 and CD3ζ/4-1BB, for cancer immunotherapy.
Researchers at Nagoya University have identified a potential therapeutic agent by developing a novel knockout mouse that presents the symptoms mimicking FTLD patients.
Nagoya University researchers have successfully identified a drug for the treatment of JMML using integrated molecular profiling.
Researchers in Nagoya University have successfully identified the therapeutics of SBMA targeting the spatiotemporal dysregulation of signaling pathways in SBMA.
A-70 Novel biomarker to predict immunotherapy effect on cancer patients
Nagoya University researchers have successfully elucidated functional molecular mechanism of the ISLR, immunoglobulin superfamily containing leucin e-rich repeat, to develop highly sensitive biomarker as a checkpoint protein for Immunotherapies.